Xizang Haisco Pharmaceutical Co., Ltd
Quick facts
Marketed products
- HSK21542 tablet · Oncology
HSK21542 is a small-molecule inhibitor that targets specific kinases involved in cellular signaling pathways.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: